Sugi Predict

Sugi Predict / Targets / NOX1

NOX1

NADPH oxidase 1 · Q9Y5S8 · NOX1 on Sugi Atlas →

26,756 patent compounds predicted against NOX1, 15,832 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL342449 SCHEMBL342449 1.00 13/20
SCHEMBL205578 SCHEMBL205578 0.48 13/20
SCHEMBL236458 SCHEMBL236458 1.00 12/20
SCHEMBL239600 SCHEMBL239600 1.00 12/20
SCHEMBL239261 SCHEMBL239261 0.79 12/20
SCHEMBL225829 SCHEMBL225829 0.65 12/20
SCHEMBL561135 SCHEMBL561135 0.51 12/20
SCHEMBL560225 SCHEMBL560225 1.00 11/20
SCHEMBL237910 SCHEMBL237910 0.65 11/20
SCHEMBL239549 SCHEMBL239549 0.65 11/20
SCHEMBL299552 SCHEMBL299552 0.65 11/20
Phenothiazine Phenothiazine (SCHEMBL688772) 0.63 11/20
SCHEMBL885118 SCHEMBL885118 0.63 11/20
SCHEMBL240209 SCHEMBL240209 0.59 11/20
SCHEMBL885158 SCHEMBL885158 0.57 11/20
SCHEMBL26797 SCHEMBL26797 0.55 11/20
SCHEMBL985063 SCHEMBL985063 0.52 11/20
SCHEMBL885286 SCHEMBL885286 0.50 11/20
Phenothiazine Phenothiazine (SCHEMBL9114) 1.00 10/20
Phenothiazine Phenothiazine (SCHEMBL561001) 0.77 10/20

Clinical trials — most relevant to NOX1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cardiotoxicity in Breast Cancer Patients PHASE4RECRUITING
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis PHASE4NOT_YET_RECRUITING
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing. PHASE1/PHASE2COMPLETED
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis PHASE2COMPLETED
Salt-Sensitivity and Immunity Cell Activation PHASE1/PHASE2ACTIVE_NOT_RECRUITING
NOX-100 for Preventing Hypotension During Hemodialysis PHASE2COMPLETED
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers PHASE1COMPLETED
NOX-A12 First-in-human (FIH) Study PHASE1COMPLETED
NOX-E36 First-in-Human (FIH) Study PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
Effect of IFN-γ on Innate Immune Cells PHASE1COMPLETED
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM EARLY_PHASE1RECRUITING
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
Covid-19: Possible Role of Neutrophil Extracellular Traps nanUNKNOWN
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 nanCOMPLETED
Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease nanUNKNOWN
Flow Mediated Dilation in Association With Hyperuricemia nanUNKNOWN
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure nanUNKNOWN
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep nanCOMPLETED
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis nanCOMPLETED
Effect Inhaled Nitric Oxide in Adult Liver Transplant nanNOT_YET_RECRUITING
Effect of Omega 3 on Oxidative Stress and Nutritional Status of Children on Regular Dialysis nanRECRUITING
Switching to Low Oxidant Content Cigarettes in Adult Smokers nanCOMPLETED
Anti-inflammatory Effects of Fiber nanCOMPLETED
Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease nanUNKNOWN
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NOX1 binder may also engage these)

ProteinNameSimilarity
Q9WV87 — 0.987 Q9WV87 →
Q8CIZ9 — 0.974 Q8CIZ9 →
Q8BWB6 — 0.957 Q8BWB6 →
P98200 — 0.946 P98200 →
Q8NFT2 — 0.942 Q8NFT2 →
Q91YD4 — 0.942 Q91YD4 →
Q95L74 — 0.942 Q95L74 →
P52649 — 0.941 P52649 →
O46522 — 0.940 O46522 →
TRPC7 Short transient receptor potential channel 7 0.939 landscape →
C7EXK4 — 0.939 C7EXK4 →
P70704 — 0.939 P70704 →
Q61093 — 0.939 Q61093 →
CYBB NADPH oxidase 2 0.938 landscape →
KCNT2 Potassium channel subfamily T member 2 0.937 landscape →
Q9WVC5 — 0.937 Q9WVC5 →
E9PTA2 — 0.937 E9PTA2 →
Q9NTI2 — 0.936 Q9NTI2 →
Q9WU81 — 0.936 Q9WU81 →
Q9ULV1 — 0.936 Q9ULV1 →
Q9Y2Q0 — 0.936 Q9Y2Q0 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.935 landscape →
Q9H3R1 — 0.935 Q9H3R1 →
Q58CV5 — 0.934 Q58CV5 →
Q9IA05 — 0.934 Q9IA05 →
Q8TED4 — 0.933 Q8TED4 →
D3Z649 — 0.933 D3Z649 →
Q6UVM4 — 0.933 Q6UVM4 →
Q61088 — 0.932 Q61088 →
Q5U4X8 — 0.932 Q5U4X8 →